Zahl Per-Henrik, Maehlen Jan
Divisjon for epidemiologi, Nasjonalt folkehelseinstitutt, Postboks 4404, 0403 Nydalen.
Tidsskr Nor Laegeforen. 2004 Sep 9;124(17):2238-9.
In Norway and Sweden, the introduction of mammography screening programmes has been associated with about a 50% increase in breast cancer incidence for the screened age groups and almost stable incidence in higher age groups. This suggests that mammography screening results in a substantial degree of overdiagnosis.
In a prospective cohort study of the Norwegian mammography programme we recorded the incidence of breast cancer among women aged 50 to 69 years offered mammography screening as well as the incidence of interval cancer among those attending, and breast cancer among those not attending. We used these data to calculate the incidence of cancer detected by screening among those screened.
The incidence of invasive cancer at second and third screening is 2.4 times higher than expected. We estimated that only 42% of the screening-detected invasive cancers would have developed into clinical disease in the absence of a screening programme. When ductal carcinoma in situ is added, only 34% of the screening-detected cancers would have developed into clinical disease.
Two thirds of breast cancers detected by screening are overdiagnosed.
在挪威和瑞典,乳腺钼靶筛查项目的引入与筛查年龄组的乳腺癌发病率增加约50%相关,而较高年龄组的发病率几乎保持稳定。这表明乳腺钼靶筛查导致了相当程度的过度诊断。
在一项对挪威乳腺钼靶项目的前瞻性队列研究中,我们记录了接受乳腺钼靶筛查的50至69岁女性中的乳腺癌发病率、接受筛查者中的间期癌发病率以及未接受筛查者中的乳腺癌发病率。我们使用这些数据来计算筛查人群中通过筛查检测出的癌症发病率。
第二次和第三次筛查时浸润性癌的发病率比预期高2.4倍。我们估计,在没有筛查项目的情况下,筛查检测出的浸润性癌中只有42%会发展为临床疾病。当加入原位导管癌时,筛查检测出的癌症中只有34%会发展为临床疾病。
通过筛查检测出的乳腺癌中有三分之二是过度诊断的。